Curated News
By: NewsRamp Editorial Staff
April 23, 2024

Lisata Therapeutics Advances Lead Asset LSTA1 for Treatment of Advanced Solid Tumors

Reddit Discuss on RedditDiscuss on Substack SubstackView History of this news story on GitHub Github
Source News Release

TLDR

  • Investors can anticipate potential business development activities and various clinical and data milestones in the next 12 to 18 months.
  • Lisata Therapeutics is focused on developing certepetide (LSTA1), a cyclic peptide used in combination with chemotherapy to treat solid tumor cancers.
  • Lisata Therapeutics' advancements in cancer treatment technology have the potential to improve the lives of those battling solid tumor cancers, offering hope for a better tomorrow.
  • Lisata Therapeutics CEO David J. Mazzo discusses the company's recent advancements in developing technologies to treat solid tumor cancers in an interview with Proactive's Stephen Gunnion.

Impact - Why it Matters

The advancements in Lisata Therapeutics' lead asset, LSTA1, and its potential for treating solid tumor cancers have significant implications for the future of cancer treatment. The company's optimism about commercializing List-1 as early as 2026 under ideal conditions suggests a potential breakthrough in cancer therapy. Additionally, the potential accelerated approval based on upcoming trial results and the discussions with regulatory authorities indicate a promising outlook for patients in need of advanced solid tumor cancer treatment.

Summary

Lisata Therapeutics CEO David J. Mazzo discusses the company's focus and recent advancements in an interview with Proactive's Stephen Gunnion. Lisata Therapeutics, established through the acquisition of Cend Therapeutics by Caladrius Biosciences, is dedicated to developing technologies for treating solid tumor cancers. Their primary product, certepetide (LSTA1), is a nine amino acid cyclic peptide designed to target and penetrate tumors, used in combination with chemotherapy and other cancer treatments. Lisata has received orphan drug designations and rare pediatric disease designation for osteosarcoma in the US. The company is in discussions with regulatory authorities in Australia, the EMA, and the FDA about potential accelerated approval based on upcoming trial results, and aims to commercialize List-1 as early as 2026 under ideal conditions.

Source Statement

This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Lisata Therapeutics Advances Lead Asset LSTA1 for Treatment of Advanced Solid Tumors

blockchain registration record for the source press release.